COMPASS Pathways’ (CMPS) Overweight Rating Reiterated at Cantor Fitzgerald

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a report issued on Friday,Benzinga reports.

Several other research analysts also recently issued reports on CMPS. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Stifel Nicolaus began coverage on shares of COMPASS Pathways in a research report on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of COMPASS Pathways in a report on Tuesday, March 4th. Finally, Canaccord Genuity Group decreased their price objective on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways presently has a consensus rating of “Buy” and an average price target of $21.83.

COMPASS Pathways Stock Performance

NASDAQ CMPS opened at $2.94 on Friday. The firm’s fifty day moving average price is $3.86 and its two-hundred day moving average price is $4.72. The stock has a market cap of $272.46 million, a PE ratio of -1.34 and a beta of 2.29. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. COMPASS Pathways has a fifty-two week low of $2.88 and a fifty-two week high of $10.31.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). On average, equities analysts expect that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently bought and sold shares of CMPS. RTW Investments LP acquired a new stake in COMPASS Pathways during the 4th quarter worth about $11,714,000. Altium Capital Management LLC bought a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $5,384,000. Tang Capital Management LLC acquired a new stake in COMPASS Pathways during the fourth quarter worth approximately $3,780,000. Nantahala Capital Management LLC increased its holdings in COMPASS Pathways by 400.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $3,780,000 after purchasing an additional 800,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in COMPASS Pathways in the fourth quarter valued at approximately $2,458,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.